Solaro C, Lunardi G L, Capello E, Inglese M, Messmer Uccelli M, Uccelli A, Mancardi G L
Department of Neurological Sciences and Neurorehabilitation University of Genoa, Italy.
Neurology. 1998 Aug;51(2):609-11. doi: 10.1212/wnl.51.2.609.
We conducted an open-label trial of gabapentin (GBP) as therapy for paroxysmal symptoms (PS) in 21 MS patients, including trigeminal neuralgia (6 patients), painful tonic spasms (11), dysesthetic or paresthetic symptoms (3) and ocular ataxia (1). Complete resolution of symptoms or partial improvement was obtained, respectively, in 14 and 4 of 18 patients who ended the study. Sustained improvement with minor side effects was obtained at dosages ranging from 600 to 1200 mg/d. Our findings suggest that GBP may be effective for PS in MS and warrant a further study in a double-blind placebo-controlled trial.
我们对21例多发性硬化症（MS）患者进行了一项加巴喷丁（GBP）治疗阵发性症状（PS）的开放标签试验，这些症状包括三叉神经痛（6例患者）、痛性强直性痉挛（11例）、感觉异常或感觉迟钝症状（3例）以及眼球共济失调（1例）。在完成研究的18例患者中，分别有14例症状完全缓解，4例部分改善。在600至1200毫克/天的剂量范围内可获得持续改善且副作用较小。我们的研究结果表明，GBP可能对MS患者的PS有效，值得在双盲安慰剂对照试验中进一步研究。
